# Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years

> **NCT06891417** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 1560 (estimated)

## Conditions studied

- Chlamydia Trachomatis Immunization

## Interventions

- **BIOLOGICAL:** Chlamydia mRNA Vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06891417
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2028-01-03
- **Final completion:** 2028-01-03
- **Target enrollment:** 1560 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891417, "Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06891417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*